INSTITUTE-FOR-BIOTECH
17.9.2018 15:05:09 CEST | Business Wire | Press release
Taiwan, with high quality medical service and world’s top IT industry, has becoming one of the leaders in global healthcare technology and provider. On November 29 - 30, MEDTEX will focus on 3 key trends: Intelligent Healthcare, Next-generation Biotherapeutics, and Bio-Innovation. Jointed by over 30 world-renowned experts.
At CEO forum , leaders from Merck, Teva, Hitachi, and Nvidia will set the tune of MEDTEX by pushing the boundaries of healthcare through cross-industry collaborations and addressing the upcoming opportunities and challenges.
Follows by Digital Healthcare forum , MEDTEX welcomes Microsoft, Google, Mayo Clinic, and Extensia to discuss topics on how healthcare can leverage AI, AIoT, cloud, and supercomputing to provide a better solution for healthcare management. By incorporating the blockchain decentralization technology, we will see the next level patient-care.
The Immuno-Oncology & Next-generation Biotherapeutics forum focuses on the latest breakthrough in treatments. Starting with cell therapy, immunotherapy to unique topics including gene editing, the spotlight will include Takeda Pharmaceutical, Senior VP to deliberate topics in drug discovery using patient-Derived iPSCs; in the most current stem cell research, we have invite inspiring speakers Eva Feldman from United States to reveal one of the latest stem cell applications; transplantation in ALS. For precision medicine, IBM Watson Health, Harvard Medical University, and Canada’s Genome BC will share trends from evidence-based treatment option, clinical disease-gene discovery and liquid biopsies in cancer.
In Bioinnovation Stadium , J&J innovation center and Novartis will discuss on how to build healthcare innovation cluster and startup strategy, and how do they evaluate those candidates. Biotech organizations from Israel, Australia, Singapore, and UK will address each unique biotechnology ecosystem’s prospectus while bringing more than 15 innovative healthcare companies to showcase their latest technology.
With 400+ major medical centers, technology, pharmaceutical, medical devices organizations participating, MEDTEX and Healthcare+ Expo are for medical professionals, IT, device, pharmaceutical, and biotech companies who wants to find new opportunities and partnering with global healthcare industry players in Asia.
Come and join us, Register Now !
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005002/en/
Contact:
Taiwan Healthcare+ Expo Gordon Shen, PhD, +886-2-2655-7888 chinhuishen@ibmi.org.tw or David Yang, PhD, +886-2-2655-8168 fmyang@rbmp.org.tw
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
IFF Declares Dividend for Second Quarter 202629.4.2026 22:25:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2026 to shareholders of record as of June 18, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260429658065/en/
Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn29.4.2026 20:25:00 CEST | Press release
Strong performance reflects sustained upward momentum driven by international expansion and operational efficiencyDigital transformation initiatives in automation and artificial intelligence enhanced productivity, governance, and cost optimization Estithmar Holding Q.P.S.C. announced its financial results for the first quarter of 2026, reporting a net profit of QAR 333 million, marking a significant 97% increase compared to the same period last year. The results underscore the strength of the Company’s operating model and the successful execution of its expansion strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429718889/en/ Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn (Photo: AETOSWire) The company recorded revenues of QAR 1.455 billion, up from QAR 1.309 billion in Q1 2025. Gross profit rose to QAR 561 million compared to QAR 416 million, representing a year-on-year increase of
DC Secretary Announces Annual Determinations Committees Outcome29.4.2026 15:36:00 CEST | Press release
DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 29, 2026. Global Dealer Voting Members (for all Regions): Non-Dealer Voting Members (for all Regions): Bank of America, N.A. Citadel Americas LLC Barclays Bank plc Elliott Investment Management L.P. BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Regional Dealer Voting Member for the Americas, EMEA, Asia Ex-Japan, and Japan Determination Committees: CCP Members for the Americas, EMEA, Asia Ex-Japan, and Australia-New Zealand Determinations Committees: Mizuho Securities Co., Ltd. ICE Clear Credit LLC LCH S.A. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommitte
Driscoll's Names Wyard Stomp Chief Operating Officer and Expands Shaily Sanghvi's Role to Lead Global Strategy29.4.2026 15:00:00 CEST | Press release
Leadership announcements advance Driscoll's global ambition to scale its proven mission of delighting consumers to every market worldwide Driscoll's, the world's leading berry brand, today announced two leadership appointments to support CEO Soren Bjorn's long-term strategy to scale the company's proven, flavor-first business model globally, bringing the same deliberate approach that made Driscoll's the #2 retail food and beverage brand in the United States to consumers in every market the company serves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429432633/en/ Wyard Stomp has been appointed Chief Operating Officer (COO), a newly created role, while continuing to lead Driscoll's Europe, Middle East, and Africa (EMEA) business. As COO, Stomp will partner closely with the Executive Leadership Team to turn strategy into action, lead cross-functional initiatives, and ensure the company executes at the pace required to sup
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom